Skip to content
Medical Health Aged Care

Final day of GP25 to provide a glimpse into the future of general practice care

Royal Australian College of GPs 2 mins read

The third day of the nation’s premier annual GP conference GP25 features prominent leaders and health experts sharing their insights on a range of matters at the forefront of general practice care. 

Speakers at the conference today include Royal Australian College of GPs (RACGP) Senior Medical Educator and Inala Indigenous Health Service worker, Dr Justin Coleman, discussing what matters most in rural and remote general practice care. The last day of GP25 will also feature an international panel discussing lessons for the future of general practice from around the globe. 

RACGP President Dr Michael Wright said day three of GP25 will zero in on vital areas of general practice research and environmental sustainability. 

“General practice research is critical for growing the evidence base about the skills and value of general practices providing the highest standard of care,” he said. 

“Today will feature a ‘rapid fire’ session on innovation, leadership and research in general practice. Another session will delve into the latest developments on preventive care, including Dr Rebecca Moore discussing the loneliness epidemic impacting many patients, and the role of GPs in reducing dementia risk. Dr Tracey Purnell will also talk about how GPs can best help patients managing acne. 

“There will be a panel session featuring Dr Kim Loo, Dr Catherine Pendrey and Dr Nicole Sleeman examining healthcare’s net zero transition and how best to achieve this. The College has spoken out on the fact that climate change is the biggest current threat to the future of the Australian healthcare system, and we’re committed to helping our members make general practice care as environmentally sustainable as possible.” 

Dr Wright said the final day of GP25 will also have a strong focus on mental health care. 

“The latest RACGP Health of the Nation report revealed 71% of GPs nominated mental health as a top reason for patient presentations, up 10% since the survey began in 2017,” he said.  

“The last day of GP25 will see several speakers, including Professor Mark Morgan and Associate Professor Caroline Johnson, taking a close look at antidepressant medication and deprescribing in general practice.  

“This is an issue that is front of mind for all GPs, particularly when you consider that around one in seven Australians take antidepressants. The withdrawal effects patients experience when they discontinue antidepressants can lead to very serious health impacts, and it’s important for us to explore all avenues for making this transition as easy as possible. 

“Every life matters and securing the future of general practice care not only relieves pressure on our entire healthcare system but also ensures that all people can lead the healthier lives.” 

~ENDS   

    

RACGP spokespeople are available for interviews: 03 8699 0992 / [email protected] 

  

 


About us:

About the RACGP  

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians. Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here 


Contact details:

Media team: 03 8699 0992 / [email protected]   

Follow us on Twitter: @RACGP and Facebook.  

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.